Vyalev could provide significant cost savings in advanced Parkinson’s

Treatment with subcutaneous foslevodopa/foscarbidopa was associated with cost savings of more than 95,000per advanced Parkinson’s disease , according to findings in the Journal of Medical Economics. “The costs associated with advanced Parkinson's disease extend beyond direct medical expenditure,” K. Ray Chaudhuri, MD, professor of neurology at Kings College Hospital, and